HOMEPPL
29.9.2021 00:03:09 CEST | Business Wire | Press release
Spotahome , the Spanish-based residential platform which manages 200,000 properties in 29 different countries across Europe, has signed an agreement with UK-based tenant due diligence and guarantee firm Homeppl to provide its landlords with a tenant referencing and guarantor service for its medium and long-term lets.
With the world opening-up and embracing a post-pandemic life, demand for both medium and long-term rentals has tripled, so being able to approve tenants quickly is imperative. But the risk of tenant fraud remains high, so it is vital that landlords have secure tenant referencing systems in place.
Homeppl’s solution combines fraud detection tests, behavioural analysis and financial algorithms, as well as Open Banking data, to assess the true transactional ability of consumers from all over Europe. It has a 0% default rate, and Homeppl is so confident in its referencing solution that it also offers guarantid - a service where it acts as a guarantor for tenants it approves - giving landlords more protection and tenants more freedom.
Spotahome has embedded the Homeppl tenant and guarantor services in a new premium package for its landlords; 2,000 have already signed up in Spotahome Premium service, with numbers expected to reach 10,000 by the end of the year.
Through this partnership with Homeppl, Spotahome - already a pioneer in digital rental due to its innovative virtual tours - is further transforming the rental process in Europe making it easier for tenants to rent and safer for landlords. Thanks to Homeppl’s service, Spotahome is reducing entry barriers to rent for tenants by no longer having to charge an initial payment of between one and three months’ rent, while also providing financial and legal security to landlords by mitigating fraud, guaranteeing rent and covering the cost of any damage to property.
CEO and Co-founder of Spotahome, Alejandro Artacho said: “ This new service offered to “Premium Spotahome Landlords” in partnership with Homeppl, makes Spotahome the only platform offering rentals with no deposit and Landlords guaranteed across multiple countries in Europe and it is just a step towards making rentals more accessible, and at the same time more secure for both tenants and landlords. In the following months, Spotahome will continue to launch new functionalities becoming the European digital rental platform of reference.
CEO of Homeppl Alexander Siedes said: “With a post-COVID recovery underway, we’re delighted that Spotahome – one of the biggest online rental firms in the world – has chosen us as their tenant referencing and tenant guarantor provider. This partnership will help support rental mobility across Europe, enabling tenants to explore new cities and rent with greater freedom while protecting landlords from any financial or legal risk.”
ENDS
About Homeppl:
Homeppl creates financial inclusion. The tech for good business brings equality of opportunity to consumers of financial and property products. This allows businesses to safely transact with more consumers, including those who have been living outside the UK, are self-employed or students, and other people without a credit file. To do this, they specialise in rental data validation, and risk assessment. So far they’ve validated 100,000+ people from 80+ countries with 0 default. As a result, Homeppl are confident in finding the best tenants.
Homeppl's overall aim is to let landlords and agencies assess any tenant, and guarantee rent.
For more information: www.homeppl.com
About Spotahome:
Spotahome is one of the European leading platforms created in 2014 specialized in mid-to-long term furnished accommodation.
For more information: www.spotahome.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom